Literature DB >> 10545520

Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor.

E G Fischer1, M Riewald, H Y Huang, Y Miyagi, Y Kubota, B M Mueller, W Ruf.   

Abstract

Tissue factor (TF), the cell-surface receptor for coagulation factor VIIa, supports metastasis. Equally important for this process are (a) interactions of the TF cytoplasmic domain, which binds the mobility-enhancing actin-binding protein 280, and (b) the formation of a proteolytically active TF-VIIa complex on the tumor cell surface. In primary bladder carcinoma cells, we find that this complex localizes to the invasive edge, in proximity to tumor-infiltrating vessels that stain intensely for TF pathway inhibitor (TFPI-1), the major inhibitor of the protease activity of the complex. In culture, binding of VIIa to TF-expressing tumor cells is sufficient to allow cell adhesion, migration, and intracellular signaling on immobilized TFPI-1. Immobilized heparin, a mimic for extracellular matrix-associated proteoglycans, binds physiological concentrations of TFPI-1 in a conformation that supports TF-VIIa-dependent cell adhesion. Consistent with a functional role of TFPI-1 in complex extracellular matrices, we show that TF cooperates with integrin-mediated adhesion and migration on composite matrices that contain ligands for both integrins and the TF-VIIa complex. This study thus provides evidence for a novel mechanism of protease-supported migration that is independent of proteolytic matrix degradation but rather involves protease-dependent bridging of TF's extracellular domain to an ECM-associated inhibitor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545520      PMCID: PMC409824          DOI: 10.1172/JCI7750

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples.

Authors:  W F Novotny; S G Brown; J P Miletich; D J Rader; G J Broze
Journal:  Blood       Date:  1991-07-15       Impact factor: 22.113

2.  Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.

Authors:  T A Drake; J H Morrissey; T S Edgington
Journal:  Am J Pathol       Date:  1989-05       Impact factor: 4.307

Review 3.  Biology and biochemistry of proteinases in tumor invasion.

Authors:  P Mignatti; D B Rifkin
Journal:  Physiol Rev       Date:  1993-01       Impact factor: 37.312

4.  Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.

Authors:  R Wesselschmidt; K Likert; Z Huang; L MacPhail; G J Broze
Journal:  Blood Coagul Fibrinolysis       Date:  1993-10       Impact factor: 1.276

5.  Actin-binding protein requirement for cortical stability and efficient locomotion.

Authors:  C C Cunningham; J B Gorlin; D J Kwiatkowski; J H Hartwig; P A Janmey; H R Byers; T P Stossel
Journal:  Science       Date:  1992-01-17       Impact factor: 47.728

6.  Immunohistochemical identification of tissue factor in solid tumors.

Authors:  N S Callander; N Varki; L V Rao
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

7.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.

Authors:  L F Brown; B Berse; R W Jackman; K Tognazzi; E J Manseau; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

8.  Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor.

Authors:  C A Sprecher; W Kisiel; S Mathewes; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa.

Authors:  N S Callander; L V Rao; O Nordfang; P M Sandset; B Warn-Cramer; S I Rapaport
Journal:  J Biol Chem       Date:  1992-01-15       Impact factor: 5.157

10.  Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation.

Authors:  M E Bromberg; W H Konigsberg; J F Madison; A Pawashe; A Garen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

View more
  26 in total

1.  Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor.

Authors:  M Riewald; W Ruf
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

2.  Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion.

Authors:  S D Konduri; A Tasiou; N Chandrasekar; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.

Authors:  Seetharaman Balasenthil; Nanyue Chen; Steven T Lott; Jinyun Chen; Jennifer Carter; William E Grizzle; Marsha L Frazier; Subrata Sen; Ann McNeill Killary
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

Review 4.  Diverse functions of protease receptor tissue factor in inflammation and metastasis.

Authors:  W Ruf; E G Fischer; H Y Huang; Y Miyagi; I Ott; M Riewald; B M Mueller
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 5.  Role of the protein C receptor in cancer progression.

Authors:  Wolfram Ruf; Florence Schaffner
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 6.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Cross-talk of integrin alpha3beta1 and tissue factor in cell migration.

Authors:  Andrea Dorfleutner; Edith Hintermann; Takehiko Tarui; Yoshikazu Takada; Wolfram Ruf
Journal:  Mol Biol Cell       Date:  2004-07-14       Impact factor: 4.138

8.  Myeloid cell-synthesized coagulation factor X dampens antitumor immunity.

Authors:  Claudine Graf; Petra Wilgenbus; Sven Pagel; Jennifer Pott; Federico Marini; Sabine Reyda; Maki Kitano; Stephan Macher-Göppinger; Hartmut Weiler; Wolfram Ruf
Journal:  Sci Immunol       Date:  2019-09-20

9.  Protease-activated receptors in cancer: A systematic review.

Authors:  Na Han; Ketao Jin; Kuifeng He; Jiang Cao; Lisong Teng
Journal:  Oncol Lett       Date:  2011-04-08       Impact factor: 2.967

10.  Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.

Authors:  Malgorzata Kamocka; Morris Pollard; Mark Suckow; Wojciech P Mielicki; Elliot D Rosen
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.